Abstract
Several lines of evidence suggest that endocannabinoid signalling may influence alcohol consumption. Preclinical studies have found that pharmacological blockade of cannabinoid receptor 1 leads to reductions in alcohol intake. Furthermore, variations in endocannabinoid metabolism between individuals may be associated with the presence and severity of alcohol use disorder. However, little is known about the acute effects of alcohol on the endocannabinoid system in humans. In this study, we evaluated the effect of acute alcohol administration on circulating endocannabinoid levels by analysing data from two highly-controlled alcohol administration experiments. In the first within-subjects experiment, 47 healthy participants were randomized to receive alcohol and placebo in a counterbalanced order. Alcohol was administered using an intravenous clamping procedure such that each participant attained a nearly identical breath alcohol concentration of 0.05%, maintained over 3 h. In the second experiment, 23 healthy participants self-administered alcohol intravenously; participants had control over their exposure throughout the paradigm. In both experiments, circulating concentrations of two endocannabinoids, N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), were measured at baseline and following alcohol exposure. During the intravenous clamping procedure, acute alcohol administration reduced circulating AEA but not 2-AG levels when compared to placebo. This finding was confirmed in the self-administration paradigm, where alcohol reduced AEA levels in an exposure-dependent manner. Future studies should seek to determine whether alcohol administration has similar effects on brain endocannabinoid signalling. An improved understanding of the bidirectional relationship between endocannabinoid signalling and alcohol intake may deepen our understanding of the aetiology and repercussions of alcohol use disorder.
Keywords: alcohol, alcohol self-administration, binge drinking, endocannabinoids
© 2022 Society for the Study of Addiction. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Similar articles
-
Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse.Br J Pharmacol. 2004 Oct;143(4):455-64. doi: 10.1038/sj.bjp.0705963. Epub 2004 Sep 15.PMID: 15371286 Free PMC article.
-
Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).Psychoneuroendocrinology. 2020 Jan;111:104471. doi: 10.1016/j.psyneuen.2019.104471. Epub 2019 Oct 4.PMID: 31610409 Free PMC article.
-
Modulation of brain endocannabinoid levels by voluntary alcohol consumption in alcohol-preferring AA rats.Alcohol Clin Exp Res. 2009 Oct;33(10):1711-20. doi: 10.1111/j.1530-0277.2009.01008.x. Epub 2009 Jul 1.PMID: 19572983
-
The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism.Mini Rev Med Chem. 2007 Aug;7(8):769-79. doi: 10.2174/138955707781387920.PMID: 17692039 Free PMC article. Review.
-
Role of the endocannabinoid system in the development of tolerance to alcohol.Alcohol Alcohol. 2005 Jan-Feb;40(1):15-24. doi: 10.1093/alcalc/agh111. Epub 2004 Nov 18.PMID: 15550443 Review.
References
REFERENCES
-
- Grant BF, Chou SP, Saha TD, et al. Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiat. 2017;74(9):911-923. doi:10.1001/jamapsychiatry.2017.2161
-
- Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B. The endocannabinoid system as a target for addiction treatment: Trials and tribulations. Neuropharmacology. 2017;124:73-83. doi:10.1016/j.neuropharm.2017.05.031
-
- Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A. 2003;100(3):1393-1398. doi:10.1073/pnas.0336351100
-
- Arnone M, Maruani J, Chaperon F, et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl). 1997;132(1):104-106. doi:10.1007/s002130050326
-
- Colombo G, Agabio R, Fa M, et al. Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcohol. 1998;33(2):126-130. doi:10.1093/oxfordjournals.alcalc.a008368